Latanoprost formulation - ISTA Pharmaceuticals/Senju

Drug Profile

Latanoprost formulation - ISTA Pharmaceuticals/Senju

Latest Information Update: 07 Jun 2012

Price : $50

At a glance

  • Originator Senju Pharmaceutical
  • Developer ISTA Pharmaceuticals
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Glaucoma

Most Recent Events

  • 06 Jun 2012 ISTA Pharmaceuticals has been acquired by Bausch & Lomb
  • 29 Oct 2007 Phase-I clinical trials in Glaucoma in USA (unspecified route)
  • 29 Jun 2006 Preclinical trials in Glaucoma in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top